GLPG1690 is an orally available inhibitor of ATX, also known as lysophospholipase D. Based on this sequence of events, by inhibiting ATX, GLPG1690 may be of benefit in IPF. The gene discussed is ENPP2; the disease is idiopathic pulmonary fibrosis.